



PERXU

Program Evaluation and Research Unit

Hepatitis Testing and Treatment



University of
Pittsburgh

School of
Pharmacy

Welcome!

While we wait to start, please review ways to navigate this webinar.

If you move your **cursor** to the **bottom** of **your screen** you will see a **menu**.




This menu allows you to **control**:


- **Raise Hand**
- Access to the **Chat** box
- Access to the **Q & A** box

Video options are not available for participants. Participants can be unmuted by raising their hand and being recognized by the presenter.

Housekeeping



This session is being recorded to **Tomorrow's Healthcare**



If you used a forwarded link, we need your **email address**



Pose questions in the chat to **All Participants**



Please complete the post-session **evaluation**



University of
Pittsburgh

School of
Pharmacy

PER_XU

Continuing Education Information

In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and The Jewish Healthcare Foundation. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. **1.25 hours is approved for this course.**

As a Jointly Accredited Organization, University of Pittsburgh is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. University of Pittsburgh maintains responsibility for this course. Social workers completing this course receive **1.25 continuing education credits.**



University of
Pittsburgh

School of
Pharmacy

PERXU

Disclosures

No members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.



University of
Pittsburgh

School of
Pharmacy

PERXU

Disclaimer

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses, and any off-label uses.

Mutual Agreement

- Everyone on every PERU webinar is **valued**. Everyone has an expectation of **mutual, positive regard** for everyone else that respects the **diversity** of everyone on the webinar.
- We operate from a **strength-based, empathetic, and supportive** framework – with the people we serve, and with each other on PERU webinars.
- We encourage the use of **affirming language** that is not discriminatory or stigmatizing.
- We treat others as **they** would like to be treated and, therefore, avoid argumentative, disruptive, and/or aggressive language.



University of
Pittsburgh

School of
Pharmacy

PERU

Mutual Agreement (continued)

- We strive to: **listen** to each person, avoid interrupting others, and seek to **understand** each other through the Learning Network as we work toward the highest quality services for COE clients.
- Information presented in Learning Network sessions has been vetted. We recognize that people have different opinions, and those **diverse perspectives** are welcomed and valued. Questions and comments should be framed as **constructive feedback**.
- The Learning Network format is **not conducive to debate**. If something happens that concerns you, please send a chat during the session to the panelists and we will attempt to make room to address it either during the session or by scheduling time outside of the session to process and understand it. Alternatively, you can reach out offline to your PERU point of contact.



University of
Pittsburgh

School of
Pharmacy

PERXU

Acknowledgements

- The Centers of Excellence is a partnership of the University of Pittsburgh's Program Evaluation and Research Unit and the Pennsylvania Department of Human Services; and is funded by the Pennsylvania Department of Human Services, grant number 601747.
- COE vision: The Centers of Excellence will ensure care coordination, increase access to medication-assisted treatment and integrate physical and behavioral health for individuals with opioid use disorder.



University of
Pittsburgh

School of
Pharmacy

PERXU

Hepatitis Testing and Treatment

James Ealy



AIDS CARE GROUP

Learning Objectives

- ▶ Define **hepatitis**.
- ▶ Describe the relationship between **substance use** and hepatitis infection, including **transmission routes** and **risk factors**.
- ▶ List strategies for **harm reduction**, including **screening** for and **treating** other infectious diseases (such as HIV) and addressing **injection drug use** behaviors.
- ▶ Describe the importance of ongoing **follow-up care**, including **monitoring** for reinfection and liver **disease progression**, and providing **ongoing support** and **resources** for patients.



AIDS CARE GROUP

History and Hepatitis 101

Agency
History

Viral
Hepatitis

Prevention
/Treatment



AIDS CARE GROUP

Substance Use & Hepatitis

Injection
Drug Use

HCV Risk
Factors

Sexual &
Other Risks



AIDS CARE GROUP

Harm Reduction

Understanding Harm Reduction

Link of Sex & Drugs

Ongoing Prevention



AIDS CARE GROUP

HCV Patients & Support

HIV/STI Screening

Interpreting Lab
Results

Screening vs.
Diagnosis



AIDS CARE GROUP

Follow Up After HCV Cure

- ▶ Recovery
- ▶ Life after HCV Cure
- ▶ Reinfection



AIDS CARE GROUP



Questions



AIDS CARE GROUP

References

- ▶ Centers for Disease Control and Prevention. (2022) Hepatitis C. <https://www.cdc.gov/hepatitis/hcv/index.htm#:~:text=Hepatitis%20C%20is%20a%20liver,to%20prepare%20and%20inject%20drugs.>
- ▶ Harm Reduction Coalition. (n.d.). Hepatitis C. <https://harmreduction.org/issues/hepatitis-c>
- ▶ Substance Abuse and Mental Health Services Administration. (2011). TIP 53: Addressing Viral Hepatitis in People With Substance Use Disorders. Retrieved April 11, 2023, from <https://store.samhsa.gov/product/TIP-53-Addressing-Viral-Hepatitis-in-People-With-Substance-Use-Disorders/SMA11-4653>



AIDS CARE GROUP